精蛋白锌重组人胰岛素混合注射液治疗2型糖尿病患者31例

目的研究精蛋白锌重组人胰岛素混合注射液对2型糖尿病患者的疗效影响及并发症发生率。方法采用随机数字表法将62例患者随机分为观察组和对照组，各31例。对照组采用降糖药物治疗，观察组采用胰岛素联合降糖药物治疗，比较两组患者血糖控制效果、治疗依从性、药物不良反应发生率和糖尿病并发症发生率。结果观察组患者空腹血糖为（7．07±0．25）mmol／L，餐后2h血糖（8．43±0．37）mmol／L，糖化血红蛋白（6．92±0．44）％，对照组分别为（7．34±0．30）mmol／L，（9．12±0．48）mmol／L，（7．29±0．54）％，组间比较差异具有统计学意义（P〈0．05）。观察组患者糖尿病急性并发症发生率为16．13％，慢性并发症发生率为9．68％；对照组患者分别为38．71％和29．03％，组间比较差异具有统计学意义（P〈0．05）。结论精蛋白锌重组人胰岛素混合注射液有助于患者血糖控制，可有效降低药物不良反应和糖尿病并发症发生率。

Recombinant Human Insulin Isophane Injection in the Treatment of Type 2 Diabetes Mellitus in 31 Cases

Objective To study the impact of Recombinant Human Insulin Isophane Injection in the traetment of type 2 diabetes melli- tus. Methods Using random number table method, 62 patients with type 2 diabetes mellitus were randomly divided into trial group and control group, each 31 cases. The control group using glucose- lowering drug treatment, the observation group using Recombinant Human Insulin Isophane Injection joint glucoselowering drug treatment, compared with two groups of patients, blood sugar control effect, treatment adherence, adverse drug reaction rate and diabetes complications. Results The observation group patients fasting blood sugar for （7. 07±0. 25）mmol/L, eat hind 2 h blood sugar （8.43±0.37）mmol/L, glycated hemoglobin （6.92±0.44）%, the control group were （7.34 ±0. 30） mmol/L, （9.12 ±0. 48） mmol/L, （7.29 ±0. 54）%, comparative differences between groups were statistically significant （P 〈0. 05）. The observation group diabetes complications in patients with acute was 16. 13%, and chronic complication rate is 9.68%, and the patients with acute complications of chronic was 38.71%, and chronic concurrent rate was 29.03% and comparative differences between groups were statistically significant（ P 〈 0.05）. Conclusion Recombinant Human Insulin Isophane Injection help patients blood sugar control, can effectively reduce the adverse drug reactions and diabetes complications.